During the past decade, Hiroshima University Hospital conducted 108 clinical trials. In the 10-year time frame, 108 clinical trials started and 46 clinical trials were completed, i.e. on average, 42.6% percent of trials that started reached the finish line to date. In the past 5 years, 62 clinical trials started and 34 clinical trials were completed. i.e. 54.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hiroshima University Hospital" #1 sponsor was "Hoffmann-La Roche" with 21 trials, followed by "Eli Lilly and Company" with 13 trials sponsored, "Pfizer" with 11 trials sponsored, "Takeda" with 10 trials sponsored and "Shire" with 10 trials sponsored. Other sponsors include 75 different institutions and companies that sponsored additional 57 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hiroshima University Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Incyte Corporation" with 4 trials as a collaborator, "Chugai Pharmaceutical" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Hiroshima University Hospital" are "Ulcerative Colitis" (12 trials), "Hemophilia A" (5 trials), "Non-Small Cell Lung Cancer" (5 trials), "Breast Cancer" (4 trials) and "Breast Neoplasms" (4 trials). Many other conditions were trialed in "Hiroshima University Hospital" in a lesser frequency.

Most popular intervention types in "Hiroshima University Hospital" are "Drug" (123 trials), "Biological" (16 trials), "Other" (16 trials), "Procedure" (6 trials) and "Device" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (43 trials), "Cisplatin" (12 trials), "Atezolizumab" (10 trials), "Carboplatin" (10 trials) and "Docetaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima University Hospital" are 128 trials for "All" genders, 7 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Hiroshima University Hospital". undefined are not yet recruiting, 32 are recruiting, 41 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 54 completed trials in Hiroshima University Hospital, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima University Hospital, 6 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 99 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".